Vector system

Abstract

The present invention relates to retroviral vector genomes and to vector systems comprising such genomes. In particular the present invention relates to a retroviral vector genome comprising two or more NOIs operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs suitable for treating a neurodegenerative disorder; and a lentiviral vector genome which encodes tyrosine hydroxylase, GTP-cyclohydrolase I and optionally Aromatic Amino Acid Dopa Decarboxylase.

Description

REFERENCE TO RELATED APPLICATIONS [0001] This application is a divisional of U.S. application Ser. No. 10 / 408,456, allowed, which is a Continuation-in-Part of PCT / GB01 / 04433, filed on Oct. 5, 2001, designating the U.S., published on Apr. 11, 2002 as WO 02 / 29065, and claiming priority from GB 0024550.6, filed on Oct. 6, 2000. All of the above-mentioned applications, as well as all documents cited herein, and documents referenced or cited in documents cited herein, are incorporated by reference.[0002] The present invention relates to a vector system. In particular, the present invention relates to a lentiviral vector system for the treatment of Parkinson's disease. BACKGROUND [0003] Parkinson's Disease [0004] Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of the nigrostriatal pathway. Although the cause of Parkinson's disease is not known, it is associated with the progressive death of dopaminergic (tyrosine hydroxylase (TH) positive) mesencephalic ...

AI Technical Summary

Benefits of technology

The patent text describes a new invention related to viral vector genomes and vector systems. The invention provides a retroviral vector genome that includes two or more nucleotide sequences of interest (NOIs) that can be used to treat neurodegenerative disorders. The NOIs can be linked by one or more internal ribosome entry sites (InRES). The genome can also include a lentiviral vector system that can deliver an RNA genome to a recipient cell and produce a viral particle for use in treating or preventing diseases. The invention also provides a bicistronic cassette that includes a nucleotide sequence capable of encoding tyrosine hydroxylase and a nucleotide sequence capable of encoding GTP-cyclohydrolase I, as well as a tricistronic cassette that includes a nucleotide sequence capable of encoding tyrosine hydroxylase, a nucleotide sequence capable of encoding GTP-cyclohydrolase I, and a nucleotide sequence capable of encoding Aromatic Amino Acid Dopa Decarboxylase.

Problems solved by technology

There is currently no satisfactory cure for Parkinson's disease.

However, functional recovery has only been partial, and the efficacy and reproducibility of the procedure is limited.

Also, there are ethical, practical and safety issues associated with using tissue derived from aborted human foetuses.

Moreover, the large amounts of tissue required to produce a therapeutic effect is likely to prove to be prohibitive.

However, xenotransplantation requires immunosuppressive treatment and is also controversial due to, for example, the possible risk of cross-species transfer of infectious agents.

Another disadvantage is that, in current grafting protocols, no more than 5-20% of the expected numbers of grafted TH positive neurons survive.

Although in vivo and ex vivo gene therapy strategies for the treatment of Parkinson's disease have already been proposed (Dunnet and Bjorklund (1999) as above; Raymon et al (1997) Exp. Neurol. 144:82-91; Kang (1998) Mov. Dis. 13: 59-72) significant progress in this technology has been hampered by the limited efficiency of gene transfer and expression in the target cells.

One problem in this regard is that the target cells are usually non-dividing cells (i.e. neurones) which are notoriously recalcitrant to transduction.

This is because, according to WO 98 / 18934 the efficiency of an IRES is often low and tissue dependent making the strategy undesirable when one is seeking to maximise the efficiency of metabolic conversion of, for example, tyrosine through to dopamine.

The use of IRES elements in retroviral vectors has been investigated (see, for example, WO 93 / 0314) but expression of the cDNA situated downstream of the IRES has often been found to be inefficient.

If incorporation of the heterologous gene and associated regulatory elements dramatically increases the size of the viral genome, then there is a significant risk that it will no longer be able to be successfully packaged, or at least that packaging efficiency will be significantly reduced.

Images